

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/08678 A1

(51) International Patent Classification⁷: **A61K 31/33, 31/40, 31/445, 31/55, C07D 207/08, 207/10, 207/12, 207/14, 207/16, 211/18, 211/20, 211/22, 211/24, 211/26, 211/30, 211/32, 225/00**

(21) International Application Number: **PCT/US00/20553**

(22) International Filing Date: **28 July 2000 (28.07.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/146,144 30 July 1999 (30.07.1999) US

(71) Applicant: **UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION [US/US]; A144 ASTeCC, Lexington, KY 40506-0286 (US).**

(72) Inventors: **DWOSKIN, Linda, P.; 116 Louisiana Avenue, Lexington, KY 40502 (US). CROOKS, Peter, A.; 3233 Raven Circle, Lexington, KY 40502 (US). JONES, Marlon, D.; 1900 Garden Springs, Apt. #43, Lexington, KY 40504 (US).**

(74) Agents: **WEIFFENBACH, Cameron, K. et al.; McDermott, Will & Emery, 600 13th Street, N.W., Washington, DC 20005-3096 (US).**

(81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.**


(84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Published:

— *With international search report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CIS-2,6-DISUBSTITUTED PIPERIDINES FOR THE TREATMENT OF PSYCHOSTIMULANT ABUSE AND WITHDRAWAL, EATING DISORDERS, AND CENTRAL NERVOUS SYSTEM DISEASES AND PATHOLOGIES**



(57) Abstract: **Cis-2,6-disubstituted piperidine analogs, or lobeline analogs, having general formula (I) are used to treat diseases of the central nervous system, drug abuse and withdrawal therefrom as well as to treating eating disorders.**

THIS PAGE BLANK (USPTO)

**CIS-2,6-DISUBSTITUTED PIPERIDINES FOR THE TREATMENT OF
PSYCHOSTIMULANT ABUSE AND WITHDRAWAL, EATING DISORDERS, AND
CENTRAL NERVOUS SYSTEM DISEASES AND PATHOLOGIES**

This application claims the benefit of Provisional Application No. 60/146,144, filed on July 30, 1999.

Field of Invention

The present invention relates to lobeline analogs, specifically *cis*-2,6-disubstituted piperidines, and their method of use in the treatment of diseases and pathologies of the central nervous system (CNS), the treatment of drug abuse and withdrawal therefrom as well as to the treatment of eating disorders such as obesity.

Background of the Invention

Alpha-Lobeline (lobeline), a lipophilic nonpyridino, alkaloidal constituent of Indian tobacco, is a major alkaloid in a family of structurally-related compounds found in *Lobelia inflata*. Lobeline has been reported to have many nicotine like effects, including tachycardia and hypertension (Olin et al., 1995), hyperalgesia (Hamann et al., 1994) and improvement of learning and memory (Decker et al., 1993). Lobeline has high affinity for nicotinic receptors (Lippiello et al., 1986; Broussolle et al., 1989). However, no obvious structural resemblance of lobeline to nicotine is apparent and structure function relationships between S(-)-nicotine and lobeline do not suggest a common pharmacophore (Barlow et al., 1989). Also, differential effects of lobeline and nicotine suggest that these drugs may not be active through a common CNS mechanism, even though lobeline has been considered a mixed nicotinic agonist/antagonist.

Lobeline evokes dopamine (DA) release from rat striatal slices. However, lobeline evoked DA release is neither dependent upon extracellular calcium nor is it sensitive to mecamylamine, a noncompetitive nicotinic receptor antagonist. Thus, lobeline evoked DA release occurs via a different mechanism than does nicotine to evoke DA release (Teng et al., 1997, 1998; Clarke et al., 1996). In this respect, lobeline also inhibits DA uptake into rat striatal synaptic vesicles via an interaction with the dihydrotetraabenazine (DTBZ) site on vesicular monoamine transporter-2 (VMAT2), thus increasing the cytosolic DA available for reverse transport by the plasma membrane transporter (DAT) (Teng et al., 1997, 1998). Thus, lobeline interacts with nicotinic receptors and blocks nicotine-evoked DA release, but also interacts with DA transporter proteins to modify the concentration of DA in the cytosolic and vesicular storage pools, thereby altering subsequent dopaminergic neurotransmission.

SUMMARY OF THE INVENTION

The present invention is directed to a method of treating an individual who suffers from a disease or pathology of the central nervous system (CNS) or for treating an individual for drug dependence or withdrawal for drug dependence. The method comprises of administering to the 5 individual an effective amount of a cis-2,6-substituted piperidino compound; i.e., a lobeline analog, including pharmaceutically acceptable salts of such compounds thereof. As used herein, an "effective amount" refers to an amount of a drug effective to reduce an individual's desire for a drug of abuse or for food, or for alleviating at least one of the symptoms of the disease or pathological symptom of a CNS pathology.

10 The compound can be administered alone, combined with an excipient, co-administered with a second drug having a similar or synergistic effect. The compound is administered subcutaneously, intramuscularly, intravenously, transdermally, orally, intranasally, intrapulmonary or rectally. The use of cis-2,6-disubstituted piperidines and derivatives thereof in treating diseases or pathologies of the CNS is implicated. In particular, the treatment of 15 dependencies of such drugs as cocaine, amphetamine, caffeine, nicotine, phencyclidine, opiates, barbiturates, benzodiazepines, cannabinoids, hallucinogens, and alcohol is implicated. Also, the treatment of eating disorders such as obesity is implicated.

In a preferred aspect of the invention, the method of treatment reduces an individual's 20 desire for the drug of abuse or for food by at least one day, but it is also preferred that the treatment method further comprise administering behavior modification counseling to the individual. Although the compound of the present invention is contemplated primarily for the treatment of drug abuse and withdrawal and for eating disorders, other uses are also suggested by the studies discussed herein. Thus, cognitive disorders, brain trauma, memory loss, psychosis, 25 sleep disorders, obsessive compulsive disorders, panic disorders, myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Huntington's disease, attention deficit disorder, hyperkinetic syndrome, chronic nervous exhaustion, narcolepsy, motion sickness and depression, and related conditions are considered to be susceptible to treatment with a compound of the present invention.


As shown by the results of the studies described herein, lobeline analogs are found to be 30 effective in inhibiting uptake of extracellular DA by cells of the CNS. Some of these analogs are also nicotinic receptor antagonists. Either or both mechanisms can thereby work to alter the distribution of the intracellular DA pools and as a result alter extracellular DA concentration.

As used herein the term "lobeline" refers to a compound having the general chemical formula 2-[6-(β -hydroxyphenethyl)-1-methyl-2-piperidyl]-acetophenone. The term "lobeline analogs" and equivalents thereof as used herein, refers to chemical derivatives of lobeline obtained by oxidation or reduction of lobeline, others obtained by esterification of lobeline and 5 redox derivatives, as well as various substitutions at the N-position of the piperidinyl moiety.

DETAILED DESCRIPTION OF THE INVENTION

The 2,6-disubstituted piperidine lobeline analogs of the present invention include those contemplated by the following formula (I), without regard to chirality:

10



wherein:

n is zero or an integer in the range from 1 to 3;

X¹--Y¹ and X²--Y² are the same or are independently different from one another and 15 represent a saturated carbon-carbon bond, a *cis*-carbon-carbon double bond, a *trans*-carbon-carbon double bond, a carbon-carbon triple bond; a saturated sulfur-carbon bond, a saturated selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, a N-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower straight chain or branched alkyl, a nitrogen-carbon double bond, or a nitrogen-nitrogen double bond;

R¹ and R⁴ are the same or are independently different from one another and represent 20 hydrogen or a lower straight chain or branched alkyl or R¹ and R⁴ together form a ring including a -CH₂-, -CH₂CH₂-, -CH₂CH₂-CH₂-, -*cis*-CH=CH-, -*cis*-CH₂-CH=CH- or -*cis*-CH₂=CH-CH₂- moiety;

R² and R³ are the same or are independently different from one another and represent 25 a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocyclic moiety; an oxygen containing heterocyclic moiety; a sulfur containing heterocyclic moiety; a selenium containing

heterocyclic moiety; a mixed heterocyclic moiety containing at least two atoms selected from the group consisting of nitrogen, oxygen and sulfur; and an ortho, meta or para-substituted benzene;

with the proviso that when n=0, R² and R³ are unsubstituted phenyl groups, and X¹—Y¹ and X²—Y² are saturated carbon-carbon bonds, Y¹ cannot be CH₂, CHO or C=O, and Y² cannot be CH₂, CHO, or C=O.

It is preferred that when R³ and/or R⁴ is a saturated hydrocarbon ring, the ring includes, but is not limited to, cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.

10 It is further preferred that when R³ and/or R⁴ is an unsaturated hydrocarbon ring, the ring includes, but is not limited to, benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.

15 It is further preferred that when R³ and/or R⁴ is a nitrogen containing heterocyclic moiety, the moiety includes, but is not limited to, azetine, piperidine, piperazine, pyrazine, pyrazole, pyrazolidine, imidazole imidazoline, pyrimidine, hexa-hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or pyridazine, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof..

20 It is further preferred that R³ and/or R⁴ is an oxygen containing heterocyclic moiety, the moiety includes, but is not limited to, furan, tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4-oxathinan, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.

25 It is further preferred that when R³ and/or R⁴ is a sulfur containing heterocyclic moiety, the moiety includes, but is not limited to, thietane, thiophene, thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithiane, 1,4-dithiane, or thiopyranylium, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.

30 It is further preferred that when R³ and/or R⁴ is a selenium containing heterocyclic moiety, the moiety includes, but is not limited to, selenophene, including all possible substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.

It is further preferred that when R³ and/or R⁴ is a mixed heterocyclic moiety, the moiety includes, but is not limited to, thiazolidine, thiazole and oxazin, including all possible

substitution patterns, geometric and stereoisomers, racemic, diastereomeric and enantiomeric forms thereof.

The substituted benzene includes at least one substituent, where the substituent is selected from , but is not limited to, the group consisting of methyl, ethyl, propyl, isopropyl, 5 butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-dimethylamino, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, 10 isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino and nitroso.

It is preferred that when either X^1--Y^1 or X^2--Y^2 is a saturated carbon-carbon bond, Y^1 or Y^2 represents CH₂, CH-OH, CHO-alkyl where said alkyl is a lower straight chain or branched 15 alkyl, CH-OSO₂-C₆H₅, CH-OSO₂-p-C₆H₄CH₃, CH-SH, C₆H₅-SH, CH-S-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-NO₂, CH-CF₃, CH-NHOH, CH-OCHO, CH-F, CH-Cl, CH-Br, CH-I, CH-NH₂, CH-NH-alkyl where said alkyl is a lower straight chain or branched 20 alkyl, CH-N(alkyl)₂ where said alkyl is a lower straight chain or branched alkyl, CH-OCONH₂, CH-OCONH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OC(alkyl)₂ where said alkyl is a lower straight chain or branched alkyl, CH-N₃, C=O or C=S; 25 CH-O-aryl such as a phenyl, ortho-, meta-, or para-substituted phenyl where the substituent is as described above; or a hydrocarbon or heterocyclic ring such as pyridyl, furanyl, naphthyl, thiazole, selenophenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole, imidazoline, pyrimidine, pyridazine or triazine, including all possible substitution patterns, diastereomeric and enantiomeric forms thereof.

The lower straight or branched alkyl can be an alkyl group containing one to seven carbon atoms. The preferred alkyl groups are methyl and ethyl.

The above 2,6-substituted piperidino analogs are preferred in their *cis*-geometrical isomeric forms, or in their *trans* geometric forms, including all possible geometric, racemic, 30 diasteriomic, and enantiomeric forms thereof


The above *cis*-2,6-disubstituted piperidines as well as analogs thereof can be administered in their free base form or as a soluble salt. Whenever it is desired to employ a salt of a *cis*-2,6-substituted piperidine or its analog, it is preferred that a soluble salt be employed.

Some preferred salts include hydrochloride, hydrobromide, nitrate, sulfate, phosphate, tartrate, galactarate, fumarate, citrate, maleate, glycolate, malate, ascorbate, lactate, aspartate, glutamate, methanesulfonate, p-toluenesulfonate, benzenesulfonate, salicylate, propionate, and succinate salts. The above salt forms may be in some cases hydrates or solvates with alcohols and other
5 solvents.

A pharmaceutical composition containing a compound of the invention is also contemplated, which may include a conventional additive, such as a stabilizer, buffer, salt, preservative, filler, flavor enhancer and the like, as known to those skilled in the art. Representative buffers include phosphates, carbonates, citrates and the like. Exemplary
10 preservatives include EDTA, EGTA, BHA, BHT and the like. A composition of the invention may be administered by inhalation, i.e., intranasally as an aerosol or nasal formulation; topically, i.e., in the form of an ointment, cream or lotion; orally, i.e., in solid or liquid form (tablet, gel cap, time release capsule, powder, solution, or suspension in aqueous or non aqueous liquid; intravenously as an infusion or injection, i.e., as a solution, suspension or emulsion in a
15 pharmaceutically acceptable carrier; transdermally, e.g., via a transdermal patch; rectally as a suppository and the like.

Generally, the pharmacologically effective dose of a present compound is in the amount ranging from about 1×10^{-5} to about 1 mg/kg body weight/day. The amount to be administered depends to some extent on the lipophilicity of the specific compound selected, since it is expected that this property of the compound will cause it to partition into fat deposits of the subject. The precise amount to be administered can be determined by the skilled practitioner in view of desired dosages, side effects and medical history of the patient and the like.
20

The cis-2,6-disubstituted piperidino analogs of the present invention exhibit selectivity for either neuronal nicotinic acetylcholine receptors and/or the dopamine transporter protein
25 (DAT). The derivatives that are active towards the nicotinic receptor generally do not interact with the DAT, and those that interact with the DAT show only modest nicotinic receptor activity.



(II)

Table 1

5	Compound (μ M)	Ki (μ M)		Ki	
		$[^3\text{H}]\text{-Nicotine Binding}$			
		Assay	Assay		
10	1. $X^1 = X^2 = \text{CH}_2$ $Y^1 = \text{C=O}$ $Y^2 = (\text{S})\text{-CHOH}$	0.0043		45	
15	2. $X^1 = X^2 = Y^1 = Y^2 = \text{CH}_2$	14.3		3.0	
	3. $X^1 = X^2 = \text{CH}_2$ $Y^1 = \text{C=O}$ $Y^2 = (\text{S})\text{-CHOSO}_2\text{-C}_6\text{H}_4\text{-p-CH}_3$	0.0041		39	
20	4. $X^1 = X^2 = \text{CH}_2$ $Y^1 = Y^2 = \text{C=O}$	11		25	
	5. $X^1, Y^1 = X^2, Y^2 = \text{trans CH=CH}$	>100		0.8	
25	6. $X^1 = \text{CH}_2$ $Y^1 = \text{C=O}$ $X^2, Y^2 = \text{trans CH=CH}$	0.13		3.0	

	7. $X^1 = X^2 = CH_2$ $Y^1 = (S)\text{-CHOH}$ $Y^2 = (R)\text{-CHOH}$	0.93	54
5	8. $X^1 = X^2 = Y^2 = CH_2$ $Y^1 = (RS)\text{-CHOH}$	0.16	8.9
10	9. $X^1 = CH_2$ $Y^1 = (S)\text{-CHOH}$ $X^2, Y^2 = \text{trans } CH=CH$	4.2	1.3

The nine cis-2,6-disubstituted piperidino derivatives listed in Table 1 have the chemical structure of formula (II). They were assayed for nicotinic receptor interaction and inhibition of DAT activity. The cis-2,6-disubstituted piperidino analogs of the present invention exhibit selectivity for either neuronal nicotinic acetylcholine receptors and/or the dopamine transporter protein (DAT). The derivatives that are active towards the nicotinic receptor generally do not interact with the DAT, and those that interact with the DAT show only modest nicotinic receptor activity.

20 The nine compounds in Table 1 were evaluated in the high affinity [^3H]nicotine binding assay and afforded inhibition constants (K_i values) ranging from 0.0043 μM to $> 100 \mu\text{M}$. Five of these compounds were in the range of 4 - 160 nM. Three of these compounds were in the range of 0.93 - 14 μM . One compound was $> 100 \mu\text{M}$. The cis-2,6-disubstituted piperidino derivatives listed in Table 1 were also assayed for inhibition of DAT activity, i.e., inhibition of 25 [^3H]DA uptake into the dopaminergic presynaptic terminal. Nine compounds were evaluated and afforded inhibition constants (K_i values) ranging from 0.08 μM to 54 μM .

30 Removal of both functionalities of the lobeline molecule resulted in loss of affinity for the nicotinic receptor and a 100-fold more potent inhibition of the dopamine transporter compared with lobeline. Removal of either the hydroxyl group or the keto group of lobeline resulted in a 50-fold loss of affinity for the nicotinic receptor. Interestingly, the ketoalkene analog inhibited DAT 10-fold more potently than lobeline, whereas lobelanidine inhibited DAT equipotently compared to lobeline. Conversion of the hydroxy group of lobeline to a bulky tosyloxy group reduced the affinity of the nicotinic receptor by only 3-fold, but did not alter the

interaction with the DA transporter. The hydroxyalkene had a similar potency with the *meso*-transdiene (the most potent compound) in the DA uptake assay, but had 1000-fold lower affinity for the nicotinic receptor. Also, the completely defunctionalized lobeline molecule and the hydroxyalkane analog were both less potent than the *meso*-transdiene in inhibiting DA uptake
5 into striatal synaptosomes. This data indicates that appropriate structural modification of the lobeline molecule affords compounds in which the interaction with DAT is enhanced. Furthermore, in one compound, i.e., the *meso*-transdiene, the nicotinic receptor interaction has been eliminated and the compound is thus selective for inhibition of DAT.

10 The invention will now be discussed by certain examples that illustrate but do not limit the invention.

Example 1

Cis-2,6-di-trans-styrylpiperidine

1.00 g (2.95 mmol) of lobelanidine was dissolved in 15 ml of 85 % H₃PO₄ and allowed to stir overnight at 60°C. The reaction mixture was taken up in H₂O and made basic with solid K₂CO₃ (pH~8). The pH was adjusted by the addition of solid NaOH (pH~10). The aqueous solution was extracted three times with 15 ml of EtOAc. The organic layers were combined and dried over anhydrous MgSO₄. The salts were removed via filtration and solvent removed by rotary evaporation affording 0.70 g of crude product. This compound was recrystallized from MeOH affording 0.60 g of pure *cis*-2,6-di-*trans*-styrylpiperidine. Percent yield = 78.6 % Mp = 139-141°C. ¹H NMR (300 MHz, CDCl₃) δ: 1.40-1.80 (m, 6H), 2.23 (s, 3H), 2.50-2.64 (t, 2H), 6.04-6.20 (dd, 2H), 6.39-6.50 (d, 2H) and 7.10-7.38 (m, 10H); ¹³C NMR (CDCl₃) δ: 23.75, 33.56, 42.32, 68.36, 126.26, 127.38, 128.61, 130.52, 133.89 and 137.13 ppm.

Example 2

Cis-2S,6R, 8S-2-[6-(β-*para*-toluenesulfonyloxyphenethyl)-

1-methyl-2-piperidyl]-acetophenone

25 1.00 g (2.58 mmol) of lobeline hemisulfate was dissolved in 25 ml of pyridine and was added dropwise to a solution (cooled to 0°C) containing 0.60 g (3.14 mmol) of p-toluenesulfonyl chloride dissolved in 15 ml of pyridine. After addition, the reaction was allowed to stir for 2 hours and then poured into 50 ml of ice-cold water and the mixture was stirred for an additional two hours. The aqueous solution was extracted three times with 25 ml of EtOAc. The organic layers were combined and dried over anhydrous Na₂SO₄. The salts were removed by filtration and the solvent was removed by rotary evaporation affording 450 mg of a pink-colored

compound. The product was recrystallized from acetone yielding 300 mg of the product. Percent yield = 21.6 % mp = 169.1-171.0°C. ¹H NMR (300 MHz, CDCl₃) δ: 1.30-1.98 (m, 6H), 2.20 (s, 3H), 2.63-2.74 (d, 3H), 2.95-3.20 (m, 2H), 3.61-3.78 (d, 1H), 3.83-4.12 (m, 2H), 4.50-4.72 (m, 1H), 4.80-4.90 (d, 1H), 6.90-7.00 (d, 2H), 7.10-7.50 (m, 8H), 7.50-7.60 (d, 2H), 7.80-7.90 (d, 2H) and 9.85 (s, 1H); ¹³C NMR (CDCl₃) δ: 21.16, 22.25, 23.32, 23.55, 27.35, 38.29, 40.18, 40.07, 60.79, 63.69, 71.05, 125.56, 125.76, 127.39, 128.28, 128.44, 128.69, 128.77, 133.67, 133.96, 135.87, 140.03, 141.98, 144.47 and 195.21 ppm.

Example 3

Cis-2S,6R-N-methyl-6-phenacyl-2-trans-styrylpiperidine

10 1.00 g (2.58 mmol) of lobeline hemisulfate was dissolved in 15 ml of 85 % H₃PO₄ and the solution was allowed to stir for 24 hrs at 50°C . Phosphoric acid was then neutralized with K₂CO₃, and a little ice cold H₂O was added to dissolve the salts. The aqueous solution was extracted with ethyl acetate (20 ml x 3). The organic layers were combined and dried with anhydrous MgSO₄. The salts were removed by filtration and the solvent was removed via rotary evaporation, affording 0.80 g of a gummy solid, which contained mainly the *trans* isomer. Percent yield = 84.6 %. ¹H NMR (300 MHz, CDCl₃) 1.15-1.60 (m, 6H), 2.02 (s, 3H), 2.47-2.71 (m, 3H), 3.16-3.34 (dd, 1H), 5.80-6.00 (dd, 1H), 6.18-6.28 (d, 1H), and 6.90-7.38 (m, 8H) and 7.64-7.80 (d, 2H); ¹³C NMR (CDCl₃) 23.52, 32.56, 33.17, 40.52, 44.02, 59.62, 68.08, 126.00, 127.15, 127.92, 128.36, 128.44, 130.29, 132.91, 133.91, 136.95, 136.99 and 198.83 ppm.

20

Example 4

Cis-10R,2S,6R- and Cis-10S,2S,6R-N-methyl-6-[1-(2-hydroxy-2-phenyl)-ethyl]-2-trans-styrylpiperidine

25 In a 250 ml round bottom flask was added 0.80 g of *cis*-2S,6R-N-methyl-6-phenacyl-2-*trans*-styrylpiperidine, and 50 ml of ethanol. Sodium borohydride was added until all of the starting material was consumed (determined by TLC). The solution was cooled to 0°C and acetone was added in small portions to quench the reaction. The solvents were evaporated to dryness and water was added precipitating 0.75 g of an off-white crystalline solid (1:1) mixture of diastereomers, which was purified on silica eluting with 75:25 (CHCl₃/ EtOH). The yield of the product (a mixture of diastereomers) was 93.4 %. ¹H NMR (300 MHz, CDCl₃) δ: 1.17-2.06 (m, 12H), 2.12 (s, 3H), 2.35 (s, 3H), 2.50-6.20 (m, 4H), 2.70-3.20 (m, 4H), 4.78-4.80 (dd, 1H), 5.04-5.14 (dd, 1H), 5.96-6.20 (m, 2H), 6.32-6.42 (dd, 2H) and 7.04-7.34 (m, 20H); ¹³C NMR

(CDCl₃) δ: 23.69, 24.15, 26.74, 29.68, 33.26, 39.94, 41.10, 41.41, 62.93, 63.00, 65.62, 68.32, 71.76, 73.90, 125.46, 126.15, 126.19, 126.83, 127.01, 127.37, 128.16, 128.23, 128.50, 130.58, 132.61, 133.85, 136.83, 136.95, 145.32 and 145.45 ppm.

Example 5

5 Cis-2S,6R-N-methyl-6-[1-(2-hydroxy-2-phenyl)ethyl]-2-phenylethylpiperidine

0.50 g (1.55 mmol) of *cis*-2S,6R-N-methyl-6-phenacyl-2-*trans*-styrylpiperidine was dissolved in 50 ml of ethanol and placed into a Parr hydrogenation apparatus with 0.10 g of 10 % Pd-on-Carbon. After removal of air, hydrogen gas was introduced until a pressure of 40 psig was reached. The reaction was allowed to proceed for 48 hrs. The Pd catalyst was removed through 10 filtration with Celite, and ethanol was removed by rotary evaporation to afford 0.30 g of a yellow oil. The compound was purified by silica gel chromatography eluting with EtOAc to afford 0.25 g of the product. The yield was 50.0 %. ¹H NMR (300 MHz, CDCl₃) δ: 0.70-0.90 (m, 6H), 1.18 (s, 3H), 1.40-1.90 (m, 6H), 2.44-2.56 (m, 2H), 4.56-4.60 (dd, 1H) and 7.04-7.30 (m, 10H); ¹³C NMR (CDCl₃) δ: 25.77, 29.24, 29.38, 29.42, 29.46, 29.68, 31.44, 35.93, 39.07, 15 74.64, 125.50, 125.85, 127.42, 128.17, 128.35, 128.37, 142.85 and 144.91 ppm.

Example 6

High Affinity [³H]Nicotine Binding Assay

The ability to displace S(-)[³H]NIC binding from rat striatal membranes to assess interaction with the α4β2 subtype was determined. The [³H]NIC binding assay was performed 20 according to previously published methods (Romano et al., 1980; Marks et al., 1986; Crooks et al., 1995). Striata from two rats were dissected, pooled and homogenized with a Tekmar polytron in 10 vol of ice-cold modified Krebs-HEPES buffer (in mM; 20 HEPES, 118 NaCl, 4.8 KCl, 2.5 CaCl₂, 1.2 MgSO₄, adjusted to pH to 7.5). The homogenate was incubated at 37°C for 5 minutes to promote hydrolysis of endogenous acetylcholine, and centrifuged at 15,000 g for 20 25 minutes and the pellet was resuspended in 10 vol of ice-cold distilled water and incubated at 37°C for 5 minutes, followed by centrifugation at 15,000 g for 20 min. The pellet containing the striatal membranes was resuspended in 10 vol of fresh ice-cold 10% Krebs-HEPES buffer and incubated at 37°C for 10 min after which it was centrifuged at 15,000 g for 20 minutes. The latter sequence of resuspension, incubation and centrifugation was repeated. The pellet was 30 frozen under fresh Krebs-HEPES buffer and stored at -40°C until assay. Upon assay, the pellet was resuspended in Krebs-HEPES buffer, incubated at 37°C for 5 minutes and centrifuged at 15,000 g for 20 min. The final pellet was resuspended in 3.6 ml ice-cold water which provides for approximately 200 μg protein/100 μl aliquot. Competition assays were performed in

duplicate in a final volume of 200 μ l Krebs-HEPES buffer containing 250 mM Tris buffer (pH 7.5 at 4°C). Reactions were initiated by addition of 100 μ l of membrane suspension to 3 nM [3 H]NIC (50 μ l) and 1 of at least 9 concentrations of analog (50 μ l). After 90 minutes incubation at 4°C, reactions were terminated by dilution of the samples with 3 ml of ice-cold buffer followed immediately by filtration through a Whatman GF/B glass fiber filters (presoaked in 0.5% polyethyleneimine (PEI) using a Brandel Cell Harvester. Filters were rinsed 3x with 3 ml of ice-cold buffer, transferred to scintillation vials and 5 ml scintillation cocktail added. Nonspecific binding was defined as binding in the presence of 10 μ M NIC. For competition curves, the IC₅₀ values were corrected for ligand concentration (Cheng et al., 1973).

10

Example 7

[3 H]Dopamine ($[^3$ H]DA) Uptake Assay, Striatal Synaptosomal Preparation

[3 H]DA uptake was performed according to a modification of the previously reported methods (Dwoskin et al., 1999). Striata were homogenized in 20 ml of ice-cold sucrose solution (0.32 M sucrose and 5 mM sodium bicarbonate, pH 7.4) with 12 passes of a teflon-pestle homogenizer (clearance approximately .003 in). The homogenate was centrifuged at 2,000 g, 4°C for 10 min. The supernatant was centrifuged at 12,000 g, 4°C for 20 minutes. The resulting pellet was resuspended in 1.5 ml ice-cold assay buffer (in mM; 125 NaCl, 5 KCl, 1.5 KH₂PO₄, 1.5 MgSO₄, 1.25 CaCl₂, 10 glucose, 0.1 L-ascorbate, 25 HEPES, 0.1 EDTA and 0.1 pargyline; pH 7.4). The final protein concentration was 400 μ g/ml. Assays were performed in duplicate in a total vol of 500 μ l. Aliquots (50 μ l synaptosomal suspension containing 20 μ g of protein) were added to assay tubes containing 350 μ l buffer and 50 μ l of 1 of 9 concentrations (final concentration, 1 nM - 1 mM) of analog or vehicle. Synaptosomes were preincubated at 34°C for 10 min before the addition of 50 μ l of [3 H]DA (30.1 Ci/mmol, final concentration 10 nM) and accumulation proceeded for 10 min at 34°C. High affinity uptake was defined as the difference between accumulation in the absence and presence of 10 μ M GBR 12935. Preliminary studies demonstrated that at 10 minutes [3 H]DA uptake is within the linear range of the time-response curve when experiments are performed at 34°C. Accumulation was terminated by addition of 3 ml ice-cold assay buffer containing 1 mM pyrocatechol and rapid filtration through a Whatman GF/B glass fiber filter paper (presoaked with buffer containing 1 mM pyrocatecol) using a Brandel Cell Harvester. The filters were washed 3 times with 3 ml of 10 ml ice-cold buffer

containing 2 mM pyrocatechol, and then transferred to scintillation vials and radioactivity determined (Packard Model B1600TR scintillation counter, Meriden, CT). Protein concentration was determined using bovine serum albumin as the standard (Bradford, 1976). Competition curves for analog inhibition of [³H]DA uptake were generated. Nonlinear regression analysis 5 was used to fit curves either in the absence or presence of 9 concentrations of analog. IC₅₀ values were corrected for concentration of [³H]DA (Cheng-Prusoff, 1973) to yield true inhibition constants ($K_i = IC_{50}/[1 + c/K_m]$), where c is the concentration of free [³H]DA and K_m is the concentration of analog at which half maximal [³H]DA uptake is achieved. These values (K_i) were converted to p K_i before statistical analysis.

10 In the examples listed in the Table, a series of cis-2,6-disubstituted piperidines, structurally related to lobeline, were synthesized and tested for activity in the high affinity nicotinic receptor binding assay and the dopamine uptake assay to assess the interaction of these piperidines with these specific proteins on the presynaptic terminal of dopaminergic neurons in the CNS. Some of these compounds have greater selectivity for interaction with DAT than for 15 interaction with nicotinic receptors, whereas other compounds interact with both nicotinic receptors and DAT, more similar to lobeline. Other compounds were more selective for the nicotinic receptor than for DAT. These combinations of pharmacological activity are considered to be beneficial for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies.

20 The foregoing is considered as illustrative only of the principles of the invention. Further, since numerous modifications and changes will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and operation shown and described, and accordingly, all suitable modifications and equivalence thereof may be resorted to, falling within the scope of the invention claimed.

25 REFERENCES

The pertinent disclosures of the references listed below and as discussed above herein are incorporated herein by reference.

Barlow R.B. et al., "Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)cystine and (-)lobeline hydrochloride and a comparison with (-)nicotine 30 and other nicotine-like compounds," *Br. J. Pharmacol.*, 1989; 98: 799-808.

Broussolle E.P. et al., "In vivo binding of ³H-nicotine in the mouse brain," *Life Sciences*, 1989; 44: 1123-1132.

Cheng Y.C. et al., "Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (I_{50}) of an enzymatic reaction," *Biochem. Pharmacol.*, 1973; 22: 3099-3108.

5

Clarke P.B.S. et al., "Release of [3 H]noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3 H]dopamine release," *Br. J. Pharmacol.*, 1993; 45: 571-576.

10

Crooks P.A. et al., "Inhibition of nicotine-evoked dopamine release by pyridino-N-substituted nicotine analogues: a new class of nicotinic antagonist," *Drug Dev. Res.*, 1995; 36: 71-82.

15

Decker M. W. et al., "Effects of lobeline, a nicotinic receptor agonist, on learning and memory," *Pharmacol. Biochem. Behav.* 1993; 45: 571-576.

Dwoskin L.P. et al., "S-($-$)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3 H]dopamine release from rat striatal slices in a calcium-dependent manner," *J. Pharmacol. Exp. Therap.*, 1999; 288: 905-911.

20

Hamann S.R. et al., "Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and ($-$)-lobeline in the rat brainstem," *Pharmacol. Biochem. Behav.*, 1994; 47: 197-201.

25

Lippiello P.M. et al., "The binding of L-[3 H]nicotine to a single class of high affinity sites in rat brain membrane," *Mol. Pharmacol.*, 1986; 29: 448-454.

Marks M.J. et al., "Nicotine binding sites in rat and mouse brain: comparison of acetylcholine, nicotine and α -bungarotoxin," *Mol. Pharmacol.*, 1986; 30: 427-436.

30

Olin B.R. et al., *Drug Facts and Comparisons*, JB Lippincott Co., St. Louis, MO, pp 3087-3095 (1995).


Romano C. et al., "Stereospecific nicotinic receptors on rat brain membranes," *Science*, 1980; 210: 647-650.

5 Teng L.H. et al., "Lobeline and nicotine evoke [³H]-overflow from rat striatal slices preloaded with [³H]dopamine: differential inhibition of synaptosomal and vesicular [³H]dopamine uptake," *J. Pharmacol. Exp. Therap.*, 1997; 80: 1432-1444.

Teng L.H. et al., "Lobeline displaces [³H]dihydrotetraabenazine binding and releases [³H]dopamine from rat sriatal synaptic vesicles," *J. Neurochem.*, 1998; 71: 258-265.

What is claimed is:

1. A method of treating an individual for dependence on a drug of abuse, withdrawal from a drug of abuse, for an eating disorder, or for a CNS disease or pathology comprising administering to the individual an effective amount of a cis-2,6-substituted piperidino compound or pharmaceutically effective salt thereof comprising formula (I):



wherein:

n is zero or an integer from 1 to 3;

X¹--Y¹ and X²--Y² are the same or are independently different from one another and represent a saturated carbon-carbon bond, a *cis*-carbon-carbon double bond, a *trans*-carbon-carbon double bond, a carbon-carbon triple bond; a saturated sulfur-carbon bond, a saturated selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, a N-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower straight chain or branched alkyl, a nitrogen-carbon double bond, or a nitrogen-nitrogen double bond;

R¹ and R⁴ are the same or are independently different from one another and represent hydrogen or a lower straight chain or branched alkyl or R¹ and R⁴ together form a ring including a -CH₂-, -CH₂CH₂-, -CH₂CH₂-CH₂-, -*cis*-CH=CH-, -*cis*-CH₂-CH=CH- or -*cis*-CH₂=CH-CH₂- moiety;

R² and R³ are the same or are independently different from one another and represent a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocyclic moiety; an oxygen containing heterocyclic moiety; a sulfur containing heterocyclic moiety; a selenium containing heterocyclic moiety; a mixed heterocyclic moiety containing at least two atoms selected from the group consisting of nitrogen, oxygen and sulfur; and an ortho, meta or para-substituted benzene;

with the proviso that when n=0, R² and R³ are unsubstituted phenyl groups, and X¹—Y¹ and X²—Y² are saturated carbon-carbon bonds, Y¹ cannot be CH₂, CHO or C=O, and Y² cannot be CH₂, CHO, or C=O.

2. The method of claim 1, wherein said drug of abuse is selected from the group consisting of cocaine, amphetamine, caffeine, nicotine, phencyclidine, opiates, barbiturates, benzodiazepines, cannabinoids, hallucinogens, and alcohol.

3. The method of claim 1, wherein in said treatment of an individual for a CNS disease or pathology, is selected from the group consisting of cognitive disorders, brain trauma, memory loss, psychosis, sleep disorders, obsessive compulsive disorders, panic disorders, myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Huntington's disease, attention deficit disorder, hyperkinetic syndrome, chronic nervous exhaustion, narcolepsy, motion sickness and depression.

4. The method of claim 1, wherein said administering of the compounds is performed subcutaneously, intramuscularly, intravenously, transdermally, orally, intranasally, intrapulmonary or rectally.

5. The method of claim 1, wherein said administering of the compound inhibits uptake of dopamine by cells of the central nervous system of the individual.

6. The method of claim 1, wherein said administering of the compound inhibits binding of neurotransmitters or drugs to nicotinic receptors on cells of the central nervous system of the individual.

7. The method of claim 1, wherein the eating disorder includes obesity of the individual.

8. The method of claim 1, wherein the individual's desire for said drug of abuse or food is reduced for at least one day.

9. The method of claim 1, further comprising behavior modification counseling to the individual.

10. The method of claim 1, wherein said administering of the compound alleviates the symptoms of the aforesaid CNS diseases and pathologies.

11. The method of claim 1, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane.

12. The method of claim 1, wherein the unsaturated hydrocarbon ring includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene.

13. The method of claim 1, wherein the nitrogen containing heterocyclic moiety includes azetine, piperidine, piperazine, pyrazine, pyrazole, pyrazolidine, imidazole imidazoline, pyrimidine, hexa-hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or pyridazine.

14. The method of claim 1, wherein the oxygen containing heterocyclic moiety includes furan, tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4-oxathinan.

15. The method of claim 1, wherein the unsaturated sulfur containing heterocyclic moiety includes thietane, thiophene, thiophane, 2,5-dihydrothiophene, 1,3-dithiolylum, 1,3-dithiolane, 1,2-dithiolylum, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylum.

16. The method of claim 1, wherein the selenium containing heterocyclic moiety is selenophene.

17. The method of claim 1, wherein the mixed heterocyclic moiety is thiazolidine, thiazole or oxazin.

18. The method of claim 1, wherein the substituted benzene includes at least one substituent selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-dimethylamino, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino and nitroso.

19. The method of claim 1, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane; the unsaturated hydrocarbon ring includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene; the nitrogen containing heterocyclic moiety includes azetine, piperidine, piperazine, pyrazine, pyrazole, pyrazolidine, imidazole imidazoline, pyrimidine, hexahydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or pyridazine; the oxygen containing heterocyclic moiety includes furan, tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4-oxathinan; the sulfur containing heterocyclic moiety includes thietane, thiophene, thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium; the selenium containing heterocyclic moiety includes selenophene; the mixed heterocyclic moiety includes thiazolidine, thiazole or oxazin; and the substituent for the substituted benzene includes at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-dimethylamino, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

20. The method of claim 19 wherein when either X^1-Y^1 or X^2-Y^2 is a saturated carbon-carbon bond, Y^1 or Y^2 represents CH_2 , CH-OH , CHO-alkyl where said alkyl is a lower straight chain or branched alkyl, $\text{CH-OSO}_2\text{-C}_6\text{H}_5$, $\text{CH-OSO}_2\text{-p-C}_6\text{H}_4\text{CH}_3$, CH-SH , $\text{C}_6\text{H}_5\text{-SH}$, CH-S-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-NO_2 , CH-CF_3 , CH-NHOH , CH-OCHO , CH-F , CH-Cl , CH-Br , CH-I , CH-NH_2 , CH-NH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N(alkyl)_2 alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCONH_2 , CH-OCONH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCON(alkyl)_2 where said alkyl is a lower straight chain or branched alkyl, CH-N_3 , C=O or C=S ; CH-O-phenyl , substituted CH-O- phenyl where the substituent is at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, N-methylamino , N,N-dimethylamino , carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, $\text{N-methylaminomethyl}$, $\text{N,N-dimethylaminomethyl}$, carboxamide, $\text{N-methylcarboxamide}$, $\text{N,N-dimethylcarboxamide}$, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso; or a hydrocarbon or heterocyclic ring comprising pyridyl, furanyl, naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole, imidazoline, pyrimidine, pyridazine or triazine.

21. The method of claim 1, wherein the pharmaceutical salts are hydrochloride, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound.

22. The method of claim 20, wherein the pharmaceutical salts are hydrochloride, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound.


23. The method of claim 1, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms.

24. The method of claim 23, wherein said alkyl is methyl or ethyl.

25. The method of claim 20, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms.

26. The method of claim 25, wherein said alkyl is methyl or ethyl.

27. A *cis*-2,6-substituted piperidino compound or pharmaceutically effective salt thereof comprising formula (I):



wherein:

n is zero or an integer from 1 to 3;

X¹—Y¹ and X²—Y² are the same or are independently different from one another and represent a saturated carbon-carbon bond, a *cis*-carbon-carbon double bond, a *trans*-carbon-carbon double bond, a carbon-carbon triple bond; a saturated sulfur-carbon bond, a saturated selenium-carbon bond, an oxygen-carbon bond, a saturated nitrogen-carbon bond, a N-alkyl substituted saturated nitrogen-carbon bond where said alkyl is a lower straight chain or branched alkyl, a nitrogen-carbon double bond, or a nitrogen-nitrogen double bond;

R¹ and R⁴ are the same or are independently different from one another and represent hydrogen or a lower straight chain or branched alkyl or R¹ and R⁴ together form a ring including a -CH₂-, -CH₂CH₂-, -CH₂CH₂-CH₂-, -*cis*-CH=CH-, -*cis*-CH₂-CH=CH- or -*cis*-CH₂=CH-CH₂- moiety;

R² and R³ are the same or are independently different from one another and represent a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocyclic moiety; an oxygen containing heterocyclic moiety; a sulfur containing heterocyclic moiety; a selenium containing heterocyclic moiety; a mixed heterocyclic moiety containing at least two atoms selected from the group consisting of nitrogen, oxygen and sulfur; and an ortho, meta or para-substituted benzene;

with the proviso that when n=0, R² and R³ are unsubstituted phenyl groups, and X¹—Y¹ and X²—Y² are saturated carbon-carbon bonds, Y¹ cannot be CH₂, CHO or C=O, and Y² cannot be CH₂, CHO, or C=O.

28. The compound of claim 27, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane.

29. The compound of claim 27, wherein the unsaturated hydrocarbon ring includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene.

30. The compound of claim 27, wherein the nitrogen containing heterocyclic moiety includes azetine, piperidine, piperazine, pyrazine, pyrazole, pyrazolidine, imidazole, imidazoline, pyrimidine, hexa-hydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or pyridazine.

31. The compound of claim 27, wherein the oxygen containing heterocyclic moiety includes furan, tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4-oxathianin.

32. The compound of claim 27, wherein the unsaturated sulfur containing heterocyclic moiety includes thietane, thiophene, thiophane, 2,5-dihydrothiophene, 1,3-dithiolylum, 1,3-dithiolane, 1,2-dithiolylum, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4-dithiane, or thiopyranylium.

33. The compound of claim 27, wherein the selenium containing heterocyclic moiety is selenophene.

34. The compound of claim 27, wherein the mixed heterocyclic moiety is thiazolidine, thiazole or oxazin.

35. The compound of claim 27, wherein the substituted benzene includes at least one substituent selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-dimethylamino, carboxylate, methylcarboxylate,

ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino and nitroso.

36. The compound of claim 27, wherein the saturated hydrocarbon ring includes cyclobutane, cyclopentane, cyclohexane, cycloheptane or cyclooctane; the unsaturated hydrocarbon ring includes benzene, cyclopentene, cyclohexene, cycloheptene, cyclooctene or cyclopentadiene; the nitrogen containing heterocyclic moiety includes azetine, piperidine, piperazine, pyrazine, pyrazole, pyrazolidine, imidazole imidazoline, pyrimidine, hexahydropyrimidine, pyrrole, pyrrolidine, triazine, 1,2,3-triazole, 1,2,4-triazole, pyridine or pyridazine; the oxygen containing heterocyclic moiety includes furan, tetrahydrofuran, 2,5-dihydrofuran, pyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane or 1,4-oxathinan; the sulfur containing heterocyclic moiety includes thietane, thiophene, thiophane, 2,5-dihydrothiophene, 1,3-dithiolylium, 1,3-dithiolane, 1,2-dithiolylium, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithiane, 1,4-dithiane, or thiopyranlium; the selenium containing heterocyclic moiety includes selenophene; the mixed heterocyclic moiety includes thiazolidine, thiazole or oxazin; and the substituent for the substituted benzene includes at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-dimethylamino, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

37. The compound of claim 36 wherein when either X¹--Y¹ or X²--Y² is a saturated carbon-carbon bond, Y¹ or Y² represents CH₂, CH-OH, CHO-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OSO₂-C₆H₅, CH-OSO₂-p-C₆H₄CH₃, CH-SH, C₆H₅-SH, CH-

S-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-NO₂, CH-CF₃, CH-NHOH, CH-OCHO, CH-F, CH-Cl, CH-Br, CH-I, CH-NH₂, CH-NH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-N(alkyl)₂ alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCONH₂, CH-OCONH-alkyl where said alkyl is a lower straight chain or branched alkyl, CH-OCON(alkyl)₂ where said alkyl is a lower straight chain or branched alkyl, CH-N₃, C=O or C=S; CH-O-phenyl, substituted CH-O- phenyl where the substituent is at least one member selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, amino, N-methylamino, N,N-dimethylamino, carboxylate, methylcarboxylate, ethylcarboxylate, propylcarboxylate, isopropylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, vinyl, allyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso; or a hydrocarbon or heterocyclic ring comprising pyridyl, furanyl, naphthyl, thiazole, selenothenyl, oxazolyl, 1,2,3-triazole, 1,2,4-triazole, imidazoline, pyrimidine, pyridazine or triazine.

38. The compound of claim 27, wherein the pharmaceutical salts are hydrochloride, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound.

39. The compound of claim 37, wherein the pharmaceutical salts are hydrochloride, hydrobromide, sulfate, hydrosulfate, citrate, fumarate and tartrate salts of said compound.

40. The compound of claim 27, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms.

41. The compound of claim 40, wherein said alkyl is methyl or ethyl.

42. The compound of claim 37, wherein said lower straight chain or branched alkyl contains one to seven carbon atoms.

43. The compound of claim 42, wherein said alkyl is methyl or ethyl.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/20553

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS—structure

EAST/WEST—(drug depend?, eating disorder?, withdrawal) and (pyrrolidin? or piperidine? or azepidin?)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,486,362 A (KITCHELL ET AL.) 23 JANUARY 1996, see entire article, especially column 17, example 8.	1-10,21-27, 38-43 -----
Y		11-20,28-37
X	US 5,830,904 A (CROOKS ET AL.) 03 November 1998, see entire article, especially, column 1, line 30, column 5 line 55, columns 25-26 claims 1-9.	1-10,21-27,38-43 -----
Y		11-20,28-37
X	FR 2,528,834 A (SANOFI) 16 JUNE 1982, see entire article, especially table 1 and 2, pages 11-12.	27,38-43 -----
Y		28-37
X	Database CAS on STN, (Columbus, OH, USA) ACCESSION No. 103:488116 "Lobelanine" CS217195, (1982), see entire article.	1-10,21-27, -----
Y		11-20,28-37

Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
• A* document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
• E* earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
• L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
• O* document referring to an oral disclosure, use, exhibition or other means		
• P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

14 SEPTEMBER 2000

Date of mailing of the international search report

13 OCT 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
CELIA CHANG
Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/20553

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database CAS on STN (Columbus, OH, USA) ACCESSION No. 123:37615 SCHIFFRIN et al. "Electroassisted separation of metals by solvent extraction and supported-liquid memberanes", HYDROMETALL. '94, Int. symp. (1994), see RN 164256-30-8.	27
---		-----
Y		28-43
X	Database CAS on STN (Columbus, OH, USA) , ACCESSION No. 66:22229, KRACMAR et al. "Ultraviolet spectrophotometry in the control of drugs" Pharmazie (1966) see RN 134-63-4.	27
---		-----
Y		28-43
X	Database CAS on STN (Columbus, OH, USA) ACCESSION No. 72:65748, SCHOENENBERGER et al. "Action mechanism of antimicrobial beta-amino ketones" Phar. Acta helv.(1996) vol.44, no.11, pages 691-714, see RN 10122-32-4.	-----
---		27
Y		-----
		28-43
X	Database CAS on STN (Columbus, OH, USA) ACCESSION No. 128:270483, KATRITZKY et al. "A short asymmetric synthesis of 2,5-disubstituted pyrrolidines" Tetrahedron Lett (1998) vol.39 pages 1698-1700, see RN 205443-03-4 and 205443-06-7.	27
---		-----
Y		28-43

INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/20553

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 31/33, 31/40, 31/445, 31/55; C07D 207/08, 207/10, 207/12, 207/14, 207/16; 211/18, 211/20, 211/22, 211/24, 211/26, 211/30, 211/32; 225/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/183, 212, 317, 327, 329, 330, 331, 408, 423, 424, 425, 426, 428; 540/450, 482, 484, 609, 612; 546/192, 216, 219, 220, 221, 223, 224, 225, 227, 229, 232; 548/568, 570, 572, 575, 579

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

514/183, 212, 317, 327, 329, 330, 331, 408, 423, 424, 425, 426, 428; 540/450, 482, 484, 609, 612; 546/192, 216, 219, 220, 221, 223, 224, 225, 227, 229, 232; 548/568, 570, 572, 575, 579

THIS PAGE BLANK (USPTO)